BiomX (PHGE) Retained Earnings (2018 - 2026)
BiomX (PHGE) posted Retained Earnings of -$236.0 million for Q1 2026, down 219.83% sequentially from $197.0 million in Q4 2025, and down 25.31% YoY from -$316.0 million in Q1 2025.
BiomX (PHGE) Retained Earnings (2018 - 2026) Analysis & Trends
BiomX has reported Retained Earnings for 9 years, with the latest figure at -$236.0 million in Q1 2026.
- Quarterly Retained Earnings fell 25.31% year-over-year to -$236.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$236.0 million (down 25.31% YoY) and the FY2025 annual result came in at $197.0 million, up 209.01% from the prior year.
- Retained Earnings eased to -$236.0 million in Q1 2026 per PHGE's latest filing, from $197.0 million in the prior quarter.
- Over five years, Retained Earnings peaked at $197.0 million in Q4 2025 and troughed at -$236.0 million in Q1 2026.
- A 5-year average of -$34.3 million and a median of -$133.9 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings soared 226.52% in 2023, then slumped 208.82% in 2024.
- Over 5 years, Retained Earnings stood at -$136.8 million in 2022, then surged by 221.38% to $166.0 million in 2023, then plunged by 208.82% to -$180.7 million in 2024, then jumped by 209.01% to $197.0 million in 2025, then slumped by 219.83% to -$236.0 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$236.0 million, $197.0 million, and $195.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | BiomX | 361,408.40 | -806,591.60 | - | -236.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -236.04 Mn |
| Dec 31, 2025 | 196.97 Mn |
| Sep 30, 2025 | 195.42 Mn |
| Jun 30, 2025 | 194.90 Mn |
| Mar 31, 2025 | -188.36 Mn |
| Dec 31, 2024 | -180.70 Mn |
| Sep 30, 2024 | -166.18 Mn |
| Jun 30, 2024 | -175.83 Mn |
| Dec 31, 2023 | 166.05 Mn |
| Sep 30, 2023 | 165.63 Mn |
| Jun 30, 2023 | -149.57 Mn |
| Mar 31, 2023 | -143.16 Mn |
| Dec 31, 2022 | -136.80 Mn |
| Sep 30, 2022 | -130.92 Mn |
| Jun 30, 2022 | 156.87 Mn |
| Mar 31, 2022 | -116.65 Mn |
| Dec 31, 2021 | 156.02 Mn |
| Sep 30, 2021 | -98.03 Mn |
| Jun 30, 2021 | 136.59 Mn |
| Mar 31, 2021 | 134.61 Mn |